MIRA Pharmaceuticals (NASDAQ:MIRA)

BRIEF

published on 04/01/2025 at 14:05, 3 days 16 hours ago

MIRA Pharmaceuticals Advances Ketamir-2 Trial for Neuropathic Pain

Clinical Research Pharmaceutical Growth Neuropathic Pain Pipeline Expansion Ketamir-2 Trial
PRESS RELEASE

published on 04/01/2025 at 14:00, 3 days 16 hours ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
MIRA Pharmaceuticals announces Phase 1 trial initiation for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, with promising preclinical data. Expansion into topical formulation and strategic acquisition plans to advance pipeline

Clinical Development Phase 1 Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 03/24/2025 at 12:35, 11 days 17 hours ago

MIRA Pharmaceuticals to Acquire SKNY, Bolstering Drug Development

Smoking Cessation MIRA Pharmaceuticals Pharmaceutical Acquisition Weight Loss Drugs SKNY-1 Development
PRESS RELEASE

published on 03/24/2025 at 12:30, 11 days 17 hours ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
MIRA acquires SKNY Pharmaceuticals, enhancing pipeline with next-gen oral therapeutic for obesity and smoking. Strategic move to address leading causes of preventable death

Acquisition Smoking Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals
BRIEF

published on 03/13/2025 at 13:05, 22 days 17 hours ago

MIRA Pharmaceuticals Enhances Ketamir-2 with Topical Pain Treatment

Pain Management Ketamir-2 Neuropathic Pain Topical Treatment Inflammatory Pain
PRESS RELEASE

published on 03/13/2025 at 13:00, 22 days 17 hours ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIRA Pharmaceuticals introduces topical Ketamir-2 for neuropathic and inflammatory pain, expanding pain management portfolio with innovative targeted approach

MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Treatment Inflammatory Pain
BRIEF

published on 03/04/2025 at 14:05, 1 month ago

MIRA Pharmaceuticals Advances with Phase 1 Trial for Ketamir-2

Clinical Study Pharmaceutical Development Neuropathic Pain Ketamir-2 Trial Therapeutic Innovation
PRESS RELEASE

published on 03/04/2025 at 14:00, 1 month ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
MIRA Pharmaceuticals, Inc. announces Phase 1 clinical trial initiation for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, in Israel. Study aims to evaluate safety, tolerability, and pharmacokinetics

Phase 1 Clinical Trial Israel MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 12/19/2024 at 15:05, 3 months 16 days ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA

Ketamir-2 NMDA Receptor Neuropathic Pain FDA IND Submission Phase I Clinical Trials
PRESS RELEASE

published on 12/19/2024 at 15:00, 3 months 16 days ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
MIRA Pharmaceuticals submits IND application for novel oral ketamine analog Ketamir-2 to FDA, targeting neuropathic pain. Phase I trials planned to start in 2025

FDA IND Application MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

1 2 ... 4

Published on 04/05/2025 at 05:50, 37 minutes ago

Lobe Sciences Provides Corporate Update
Published on 04/05/2025 at 01:50, 4 hours 37 minutes ago

Battery X Metals Achieves Graphite Recovery Breakthrough in Partnership with Global Top 20 University in Controlled Trials
Published on 04/05/2025 at 01:00, 5 hours 27 minutes ago

AIML Announces Proposed Private Placement
Published on 04/05/2025 at 00:15, 6 hours 12 minutes ago

UniDoc Announces LIFE Offering
Published on 04/05/2025 at 00:00, 6 hours 27 minutes ago

Northern Dynasty Makes Annual Filings

View all ACCESSWIRE

Published on 04/04/2025 at 18:51, 11 hours 36 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/04/2025 at 18:30, 11 hours 57 minutes ago

Forbo shareholders approved all proposals of the Board of Directors
Published on 04/04/2025 at 18:11, 12 hours 16 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/04/2025 at 18:00, 12 hours 27 minutes ago

Sartorius to acquire microtissue business MatTek from Swedish BICO AB
Published on 04/04/2025 at 17:40, 12 hours 47 minutes ago

Genel Energy PLC: Update on arbitration regarding the Bina Bawi and Miran PSCs / Recoverable Costs Award

View all EQS

Published on 04/04/2025 at 19:18, 11 hours 9 minutes ago

Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 18:17, 12 hours 10 minutes ago

Reporting on share buyback transactions carried out between March 31 and April 3, 2025
Published on 04/04/2025 at 18:13, 12 hours 14 minutes ago

Total number of voting rights and shares making up the share capital at March 31, 2025
Published on 04/04/2025 at 17:45, 12 hours 42 minutes ago

March 2025
Published on 04/04/2025 at 17:45, 12 hours 42 minutes ago

imerys-04-04-2025-regulated-information-publication-of-the-meeting-notice

View all LES ECHOS COMFI WIRE

News